IPM Take
A vaccine programme cannot be called available when most of its target population never receives it.
The report is limited to the countries that supplied data, but that limitation is part of the finding. Europe has a seasonal vaccination model without a complete seasonal view. Low uptake and incomplete reporting leave health systems unable to distinguish a weak campaign from an invisible one.
Executive Summary
ECDC reported COVID-19 vaccination coverage for the period from 1 August 2025 to 27 March 2026. Only 19 of 30 EU/EEA countries submitted data for at least one target group. Median coverage was 6.4% among people aged 60 and over and 11.4% among people aged 80 and over, with extreme variation between countries. Only one reporting country reached at least 50% coverage in the 60-plus group.
Why it matters
- Public authorities: Need comparable, timely target-group reporting and a clear account of why coverage differs so sharply between countries.
- Clinicians: Need simple eligibility rules, reminders and opportunities to vaccinate during ordinary contact with older and high-risk patients.
- Patients / advocates: Need campaigns designed around access, confidence and convenience rather than assuming that a recommendation will produce uptake.
The most alarming number in ECDC’s report may be 6.4%. The second is 19.
The first is the median seasonal COVID-19 vaccination coverage reported among people aged 60 and over. The second is the number of EU/EEA countries, out of 30, that supplied coverage data for at least one target group. Europe is therefore looking at a campaign that reached relatively few older adults in many countries through a surveillance picture that is itself incomplete.
Between August 2025 and March 2026, about 13.9 million people aged 60 and over received a COVID-19 vaccine dose in the reporting countries. Approximately 4.6 million were aged 80 and over. Median coverage was 6.4% in the 60-plus group and 11.4% in the 80-plus group. The range was enormous: from 0.2% to 60.7% for people aged 60 and over, and from 0.4% to 85.3% for those aged 80 and over.
Such variation is not explained by epidemiology alone. It reflects different recommendations, eligibility rules, delivery models, data systems and levels of public confidence. It may also reflect whether vaccination is offered during routine primary-care contact, delivered through pharmacies, combined with influenza campaigns or left to individuals to arrange after receiving a general recommendation.
The data should be interpreted carefully. ECDC is not claiming that every country failed equally, and non-reporting countries cannot simply be assigned the median. But that uncertainty is not reassuring. A seasonal programme needs a seasonal measurement system. Without it, authorities cannot tell whether high-risk populations were reached, where access failed or whether the campaign was merely documented poorly.
The policy language around COVID vaccination has shifted from emergency mobilisation to targeted protection. That is reasonable. Older adults, people with chronic conditions, pregnant women and health workers do not all require the same offer. Targeting, however, only works when target groups can be identified, invited, vaccinated and counted.
A recommendation on a ministry website is not a pathway. A pathway includes a clear message from a trusted clinician, an appointment that is easy to obtain, supply where patients already receive care, and reminders that do not depend on digital confidence. It also includes data fast enough to correct a campaign while it is still running.
The report should therefore trigger two audits. The first is about uptake: why did so few people in many older populations receive a dose? The second is about governance: why could 11 countries not provide target-group coverage data for the period under review?
For IPM, the lesson is broader than COVID-19. Precision public health is not only deciding who benefits most. It is building a system capable of reaching those people and proving that it did.
